Breaking News

27 Feb 2015 A phase 1 trial of Boehringer Ingelheim's BACE inhibitor BI 1181181 is one hold while the company investigates adverse side effects.  See news.

25 Feb 2015 After the failure of semagacestat, scientists debate whether γ-secretase should die as a therapeutic target, or be studied some more for new, better approaches. See debate.

This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials. We strive to keep this database up-to-date and welcome you to contact us at


Back to the Top
Search Therapeutics

AD Target / Therapy Types

The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U.S. clinical trials. For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total.

Further Reading


  1. BACE Inhibitor Trial Put on Hold
  2. Semagacestat Failure Analysis: Should γ-Secretase Remain a Target?
  3. New Parkinson’s Treatments Given Green Light
  4. Amino Acid Mimicry Leads Researchers to New Resveratrol Target


  1. Resolving Controversies on the Path to AD Therapeutics
  2. Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD
  3. Of Mice and Men: Bridging the Translational Disconnect in CNS Drug Discovery
  4. Can We (Should We?) Develop “Smart Drugs” to Stave Off Age-Related Memory Loss?

Other Resources

ADDF ACCESS is a program to provide scientists in academia and small biotechnology companies with access to a virtual network of drug discovery experts and contract research organizations (CROs) that have experience developing therapies for neurodegenerative diseases.

Patient Resources